Vernalis (Apokyn & Vernalis US Commercial Operations) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Vernalis (Apokyn & Vernalis US Commercial Operations) General Information
Description
Developer of pharmaceutical products headquartered in Wokingham, England. The company develops and applies fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives, inflammation and integrates fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
- Oakdene Court, 613 Reading Road
- Winnersh
- Wokingham RG41 5UA
- England, United Kingdom
Vernalis (Apokyn & Vernalis US Commercial Operations) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vernalis (Apokyn & Vernalis US Commercial Operations) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|